This is an archive article published on September 4, 2022
Premium

How ICAR’s new vaccine against Lumpy Skin Disease, the viral infection killing India’s cattle, will work

Lumpy Skin Disease vaccine: Lumpi-ProVacInd, which could be commercially launched in a few months, is a homologous, live attenuated vaccine specifically targeted to protect cattle against the LSD virus.

A carcass of a cow who succumbed to Lumpy Skin Disease seen in Gujarat. (Express Photo: Nirmal Harindran)A carcass of a cow who succumbed to Lumpy Skin Disease seen in Gujarat. (Express Photo: Nirmal Harindran)
8 min readNew Delhi, RajkotSep 4, 2022 09:17 AM IST First published on: Sep 4, 2022 at 07:00 AM IST

The Indian Council of Agricultural Research (ICAR) is aiming to commercially launch in “four-five months” its indigenously-developed vaccine against the Lumpy Skin Disease (LSD) virus that has killed around 50,000 heads of cattle in several states since April.

Bhupendra Nath Tripathi, Deputy Director-General (Animal Sciences) of ICAR, said that Agrinnovate India, the commercialisation arm for products and technologies developed by ICAR institutes, had issued an expression of interest document for the vaccine, ‘Lumpi-ProVacInd’, last month, and that three companies had shown interest.

Advertisement

What is Lumpi-ProVacInd, and how does it work?

The vaccine, which has been jointly developed by ICAR’s National Research Centre on Equines (NRCE) at Hisar, Haryana and the Indian Veterinary Research Institute (IVRI) at Izatnagar, UP, is a live attenuated vaccine, similar to those used against tuberculosis, measles, mumps and rubella.

Latest Comment
Post Comment
Read Comments